Kerala DCA Writes To NPPA To Bring Erythropoietin Injection Under Price Control

Chennai : Following a series of raid conducted in 23 discount medical shops in Manjeri Taluk in Malappuram district in Kerala, the state drugs control department has written to the national pharmaceutical pricing authority (NPPA) to bring erythropoietin injection, used for kidney patients, under price control.

This drug is widely used by kidney and cancer patients in the districts, but shop owners are charging huge margin putting the poor patients into distress.

“Since the drug is out of price control, drug retailers and distributors are charging huge amount for one vial of 400 mg. More than one company is manufacturing the drug and supplied to different distributors with MRP above Rs 1,500. But this is sold to the hospitals and medical shops for Rs 250 or Rs 260. The hospital and community pharmacies gain exorbitant profit out of one vial”, says Dr. M Nishith, drug inspector at Malappuram.

The regulator said erythropoietin injection is widely used for dialysis patients, but it is sold without price control. Different prices are charged by different medical shops. Finding that the drug is an essential drug for kidney patients and cancer patients, he wrote to the state drug regulator for recommending it to the national drug price regulator for fixing a ceiling price for it. Dr. Nishith said several multinational companies manufacture the drug and their products are available in Kerala.

In another development, the drug inspector’s raid in 23 medical shops in Manjeri has brought out a hidden fact that the discount pharmacies, medical shops who display discount boards to attract customers, are not giving the discounts to the customers. Some chain pharmacies announce a discount of 10% to 80% to all categories of medicines, but it is found that such discount is not effected in actual prices.  He said this issue was raised by a member of the Taluk Development Committee, followed by it his office conducted the raid. Reports have been sent to the state drug controller for action.

The major flaw the regulators saw in the dealings of the medical shop owners is that some special category medicines which are out of the DPCO are sold at high prices and earn huge margins. The drug inspector said some manufacturing companies are changing the ingredients of the formulation in order to skip the DPCO for earning huge profit. He said further raids have been planned to conduct in other talukas such as Ponnani, Perinthalmanna, Thiroorangadi and Nilambur next week.

  • Related Posts

    • Pharma
    • June 9, 2025
    • 80 views
    Drug smuggling racket busted inside Ropar jail; ASI, head constable, among others arrested

    Ropar police today busted a drug smuggling racket inside Ropar jail. SSP Ropar, Gulneet Singh Khurana, said that a gang involved in smuggling drugs and other prohibited items into Ropar…

    • Pharma
    • June 9, 2025
    • 79 views
    Nepal ex-PM under fire for alleged corruption over Patanjali-linked land deal, fined $1 million

    Authorities in Nepal have charged former Prime Minister Madhav Kumar Nepal with corruption and demanded a million-dollar fine over the purchase of land by a firm owned by Indian yoga…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Drug smuggling racket busted inside Ropar jail; ASI, head constable, among others arrested

    Drug smuggling racket busted inside Ropar jail; ASI, head constable, among others arrested

    Nepal ex-PM under fire for alleged corruption over Patanjali-linked land deal, fined $1 million

    Nepal ex-PM under fire for alleged corruption over Patanjali-linked land deal, fined $1 million

    NCB seizes Rs 9.2 crore assets of ‘prime accused’ in transnational drugs trafficking case from Noida

    NCB seizes Rs 9.2 crore assets of ‘prime accused’ in transnational drugs trafficking case from Noida

    Wockhardt’s novel antibiotic Zaynich eyes $9 billion global market

    Wockhardt’s novel antibiotic Zaynich eyes $9 billion global market